Recent 8-K filings for ALZN
Highest-materiality recent filing
Alzamend Neuro regains Nasdaq compliance; avoids delisting
- Received written notice from Nasdaq Hearings Panel on Oct 14, 2024 that it has regained compliance with minimum stockholders' equity rule ($2.5M required).
- Had been notified of delisting in March 2024, appealed to Panel, granted extension until Sept 23, 2024.
-
Alzamend Neuro annual meeting: all proposals pass, including reverse stock split up to 1:10
All seven director nominees elected, including William B. Horne, Milton C. Ault III, Stephan Jackman, Henry C. Nisser, Mark Gustafson, Lynne F. McGrath, Jeffrey Oram.
-
Alzamend Neuro receives Nasdaq deficiency notice for stockholders' equity below $2.5M minimum
Stockholders' equity reported at ~$2.2M as of Jan 31, 2026, below Nasdaq's $2.5M minimum requirement for continued listing.
-
Alzamend Neuro enters $3M at-the-market equity agreement with Ascendiant Capital
Up to $3.0M in common stock may be sold periodically via ATM offering with sole agent Ascendiant Capital Markets.
-
Alzamend Neuro FY2025 cash $3.9M, equity $3.9M; $5M financing completed ahead of schedule
Cash of $3.9M at April 30, 2025 vs $0.4M prior year; stockholder equity of $3.9M vs deficit $2.6M.
-
Alzamend Neuro stockholders approve reverse stock split and Series C conversion at annual meeting
Elected eight directors including William B. Horne, Milton C. Ault III, and others with substantial support; broker non-votes of 2,270,160.
-
Exchanges 97.75 Series A shares for 87.99 Series C shares; cancels existing 640K-share warrants.
-
Net cash from financing $8.3M for six months ended Oct 31, 2024; stockholder equity improved to $3.8M from a $2.6M deficit.
-
Alzamend Neuro regains Nasdaq compliance; avoids delisting
Received written notice from Nasdaq Hearings Panel on Oct 14, 2024 that it has regained compliance with minimum stockholders' equity rule ($2.5M required).
-
Alzamend Neuro enters ATM offering for up to $6.5M in common stock
Entered ATM Sales Agreement with Ascendiant Capital Markets for up to $6.5M of common stock.
-
Alzamend Neuro announces 1-for-10 reverse stock split to regain Nasdaq compliance
Reverse split effective July 16, 2024; reduces outstanding shares from ~7.98M to ~798K.
-
Alzamend Neuro gets Nasdaq extension to meet $2.5M equity rule by Sept 23, 2024
Nasdaq Hearings Panel granted continued listing on Capital Market, subject to compliance with Listing Rule 5550(b)(1).
-
Alzamend Neuro raises up to $25M via Series A Preferred and warrants; initial $500K closed
Up to $25 million financing via Series A Convertible Preferred Stock and warrants; initial tranche of $500,000 closed May 10, 2024.
-
Alzamend Neuro dismisses Baker Tilly as auditor, appoints Haskell & White
Audit Committee dismissed Baker Tilly US, LLP on May 5, 2024; no accounting disagreements.
-
Alzamend Neuro enters $25M financing via preferred stock and warrants at 15% dividend
Initial $500,000 closing of 50 Series A Preferred shares at $10,000 each; up to $25M total.
-
Alzamend Neuro raises $400K via convertible preferred and short-term note
Sold 100 Series B preferred shares and warrants for 100K common shares to Ault Lending for $100K; total $2.1M of $6M facility drawn.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material